| scholarly article | Q13442814 |
| P50 | author | Ignacio I Wistuba | Q74766086 |
| John V Heymach | Q88721314 | ||
| Gordon B. Mills | Q28086262 | ||
| P2093 | author name string | Jing Wang | |
| John D Minna | |||
| Lauren A Byers | |||
| Lixia Diao | |||
| Pan Tong | |||
| YouHong Fan | |||
| Carmen Behrens | |||
| Ximing Tang | |||
| Robert J G Cardnell | |||
| P2860 | cites work | Expression profile-defined classification of lung adenocarcinoma shows close relationship with underlying major genetic changes and clinicopathologic behaviors. | Q38408304 |
| Inhibition of the Nrf2 transcription factor by the alkaloid trigonelline renders pancreatic cancer cells more susceptible to apoptosis through decreased proteasomal gene expression and proteasome activity | Q39251887 | ||
| Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. | Q39282659 | ||
| Thyroid transcription factor-1. | Q41756471 | ||
| Surface Adjustment of Reverse Phase Protein Arrays using Positive Control Spots | Q42540737 | ||
| Associations between TS, TTF-1, FR-α, FPGS, and overall survival in patients with advanced non-small-cell lung cancer receiving pemetrexed plus carboplatin or gemcitabine plus carboplatin as first-line chemotherapy | Q43663223 | ||
| EGFR mutation is specific for terminal respiratory unit type adenocarcinoma | Q46439042 | ||
| EGFR tyrosine kinase domain mutations are detected in histologically normal respiratory epithelium in lung cancer patients | Q46685665 | ||
| Non-parametric quantification of protein lysate arrays | Q48395052 | ||
| Significance of thymidylate synthase and thyroid transcription factor 1 expression in patients with nonsquamous non-small cell lung cancer treated with pemetrexed-based chemotherapy. | Q51443990 | ||
| The histopathology of BRAF-V600E-mutated lung adenocarcinoma. | Q51693126 | ||
| Expression profiling-based subtyping identifies novel non-small cell lung cancer subgroups and implicates putative resistance to pemetrexed therapy. | Q53201712 | ||
| Frequent ALK rearrangement and TTF-1/p63 co-expression in lung adenocarcinoma with signet-ring cell component | Q53292371 | ||
| Recurrent copy number gain of transcription factor SOX2 and corresponding high protein expression in oral squamous cell carcinoma. | Q53306176 | ||
| A patient with BRAF V600E lung adenocarcinoma responding to vemurafenib. | Q54501104 | ||
| Negative NKX2-1 (TTF-1) as Temporary Surrogate Marker for Treatment Selection During EGFR-Mutation Analysis in Patients with Non–Small-Cell Lung Cancer | Q57890600 | ||
| E2F1 overexpression correlates with thymidylate synthase and survivin gene expressions and tumor proliferation in non small-cell lung cancer | Q80139021 | ||
| Primary oncocytic adenocarcinomas of the lung: a clinicopathologic, immunohistochemical, and molecular biologic analysis of 16 cases | Q82296243 | ||
| The molecular mechanism governing the oncogenic potential of SOX2 in breast cancer | Q24309520 | ||
| The PRKCI and SOX2 oncogenes are coamplified and cooperate to activate Hedgehog signaling in lung squamous cell carcinoma | Q24337113 | ||
| c-Myc-regulated microRNAs modulate E2F1 expression | Q27861046 | ||
| The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity | Q29547693 | ||
| Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers | Q29615475 | ||
| Sex determining region Y-Box 2 (SOX2) is a potential cell-lineage gene highly expressed in the pathogenesis of squamous cell carcinomas of the lung | Q33531781 | ||
| Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors | Q33769838 | ||
| Neu differentiation factor stimulates phosphorylation and activation of the Sp1 transcription factor | Q33957454 | ||
| p16( INK4a) positively regulates cyclin D1 and E2F1 through negative control of AUF1. | Q33974856 | ||
| Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features | Q34062498 | ||
| SOX2 gene regulates the transcriptional network of oncogenes and affects tumorigenesis of human lung cancer cells | Q34277248 | ||
| Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells | Q34313686 | ||
| Abnormalities of the TITF-1 lineage-specific oncogene in NSCLC: implications in lung cancer pathogenesis and prognosis | Q34809743 | ||
| A Technical Assessment of the Utility of Reverse Phase Protein Arrays for the Study of the Functional Proteome in Non-microdissected Human Breast Cancers | Q35049524 | ||
| The relationship between TTF-1 expression and EGFR mutations in lung adenocarcinomas | Q35151853 | ||
| Intersections between pulmonary development and disease | Q35219746 | ||
| Histologic patterns and molecular characteristics of lung adenocarcinoma associated with clinical outcome | Q36013991 | ||
| Oxidative stress, mammospheres and Nrf2-new implication for breast cancer therapy? | Q36420949 | ||
| Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors. | Q36491122 | ||
| Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer | Q36568988 | ||
| An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance | Q36597042 | ||
| A 12-gene set predicts survival benefits from adjuvant chemotherapy in non-small cell lung cancer patients | Q36746536 | ||
| Inhibition of nuclear factor-erythroid 2-related factor (Nrf2) by caveolin-1 promotes stress-induced premature senescence | Q36926609 | ||
| Elevated phospho-S6 expression is associated with metastasis in adenocarcinoma of the lung | Q37038176 | ||
| The emerging role of the Nrf2-Keap1 signaling pathway in cancer | Q37271797 | ||
| ErbB4 is an upstream regulator of TTF-1 fetal mouse lung type II cell development in vitro | Q37329937 | ||
| Thyroid transcription factor-1 (TTF-1/Nkx2.1/TITF1) gene regulation in the lung | Q37336056 | ||
| Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancer | Q37438981 | ||
| Inhibition of DNA double-strand break repair by the dual PI3K/mTOR inhibitor NVP-BEZ235 as a strategy for radiosensitization of glioblastoma | Q37626600 | ||
| NKX2-1/TTF-1: an enigmatic oncogene that functions as a double-edged sword for cancer cell survival and progression | Q38114206 | ||
| A review of the evidence that ochratoxin A is an Nrf2 inhibitor: implications for nephrotoxicity and renal carcinogenicity | Q38180565 | ||
| P433 | issue | 15 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | adenocarcinoma | Q356033 |
| P304 | page(s) | 3480-3491 | |
| P577 | publication date | 2015-04-15 | |
| P1433 | published in | Clinical Cancer Research | Q332253 |
| P1476 | title | An Integrated Molecular Analysis of Lung Adenocarcinomas Identifies Potential Therapeutic Targets among TTF1-Negative Tumors, Including DNA Repair Proteins and Nrf2. | |
| P478 | volume | 21 |
| Q38743594 | AXL Inhibition Suppresses the DNA Damage Response and Sensitizes Cells to PARP Inhibition in Multiple Cancers. |
| Q27315948 | Activation of the PI3K/mTOR Pathway following PARP Inhibition in Small Cell Lung Cancer |
| Q99248353 | Collagen promotes anti-PD-1/PD-L1 resistance in cancer through LAIR1-dependent CD8+ T cell exhaustion |
| Q47134342 | Comparative gene co-expression network analysis of epithelial to mesenchymal transition reveals lung cancer progression stages. |
| Q33709790 | Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer. |
| Q53696229 | Epigenetic versus Genetic Deregulation of the KEAP1/NRF2 Axis in Solid Tumors: Focus on Methylation and Noncoding RNAs. |
| Q60938811 | FoxA1 and FoxA2 drive gastric differentiation and suppress squamous identity in NKX2-1-negative lung cancer |
| Q88683196 | IL22 Promotes Kras-Mutant Lung Cancer by Induction of a Protumor Immune Response and Protection of Stemness Properties |
| Q36963605 | IL6 Blockade Reprograms the Lung Tumor Microenvironment to Limit the Development and Progression of K-ras-Mutant Lung Cancer |
| Q88301710 | Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell Therapy |
| Q52723930 | Integrative proteomic and transcriptomic analysis provides evidence for TrkB (NTRK2) as a therapeutic target in combination with tyrosine kinase inhibitors for non-small cell lung cancer. |
| Q47161308 | Protein expression of TTF1 and cMYC define distinct molecular subgroups of small cell lung cancer with unique vulnerabilities to aurora kinase inhibition, DLL3 targeting, and other targeted therapies |
| Q58792355 | Requirement for MUC5AC in KRAS-dependent lung carcinogenesis |
| Q89753117 | STING Pathway Expression Identifies NSCLC With an Immune-Responsive Phenotype |
| Q58617545 | Sex specific function of epithelial STAT3 signaling in pathogenesis of K-ras mutant lung cancer |
| Q48247270 | TTF-1/NKX2-1 binds to DDB1 and confers replication stress resistance to lung adenocarcinomas. |
| Q37718177 | Targeted Expression of miR-7 Operated by TTF-1 Promoter Inhibited the Growth of Human Lung Cancer through the NDUFA4 Pathway |
| Q36615870 | Thyroid Transcription Factor 1 Reprograms Angiogenic Activities of Secretome. |
| Q40559745 | Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up |
| Q92340221 | ZEB1 suppression sensitizes KRAS mutant cancers to MEK inhibition by an IL17RD-dependent mechanism |
Search more.